Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update
Ocugen, Inc. (NASDAQ: OCGN) announced a conference call scheduled for February 25, 2022, at 8:30 a.m. ET to discuss its fourth quarter and full year 2021 financial results. A pre-market earnings announcement will be issued on the same day. Investors can participate via a toll-free dial-in number and a webcast. Ocugen focuses on gene therapies for blindness and co-developing Bharat Biotech’s COVAXIN™ vaccine for COVID-19. The company emphasizes its innovation in treating retinal diseases and seeks to provide updates on its business and financial performance.
- Upcoming conference call to discuss fourth quarter and full year 2021 results could indicate transparency with investors.
- Focus on innovative gene therapies for retinal diseases suggests potential for significant market impact.
- No specific financial metrics or results provided in the announcement may lead to uncertainty among investors.
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, February 25, 2022.
Ocugen will issue a pre-market earnings announcement on the same day. Investors are invited to participate on the call using the following details:
- Dial-In Number: (844) 873-7330 (toll free) or (602) 563-8473 (Int’l)
- Conference ID: 4071887
- Webcast: Available in the “Investors” section of the Ocugen website and archived for approximately 45 days following the call
About Ocugen, Inc.
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
IR@Ocugen.com
Please submit investor-related inquiries to: IR@ocugen.com
FAQ
When is Ocugen's earnings call for Q4 and full year 2021?
How can I participate in Ocugen's earnings call?
What does Ocugen focus on?
Where can I find Ocugen's pre-market earnings announcement?
